Oncology Central

Rationale for RAS mutation-tailored therapies


RAS mutations are among the most common genetic alterations found in cancerous tumors but rational criteria or strategies for targeting RAS-dependent tumors are only recently emerging. Clinical and laboratory data suggest that patient selection based on specific RAS mutations will be an essential component of these strategies.

To view restricted content, please:

Leave A Comment